R3

HRR Testing Moves Upfront in Prostate Cancer
FDA has moved talazoparib plus enzalutamide into metastatic androgen pathway modulation-naive or sensitive prostate cancer with HRR mutations. Molecular profiling can no longer be treated as a later-line exercise when it now determines first-line metastatic treatment.

FDA Redraws the TMB-High Treatment Line

Cardiometabolic screening is becoming a consumer product. Prevention is still a health-system job

Exercise is already medicine. Cardiology wants doctors to prescribe it that way

Clinicians are already asking AI what to do, not just what the diagnosis is

Fasted cardio burns more fat during exercise, but the long-term advantage disappears

Genomics Is Becoming an Acute Neurology Test

Epilepsy Treatment Does Not Have to End Breastfeeding

Alzheimer’s Blood Tests Are Changing Decisions, Not Just Diagnoses

CLL Just Moved a Noncovalent BTK Inhibitor Into First Line
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
